SMO and familial pancreatic carcinoma: In addition, pharmacological modulation of the HH pathway in mice revealed accelerated or delayed pancreatic cancer development following SMO inhibitor or HH agonist treatment, respectively (Lee et al., 2014; Rhim et al., 2014).